Gokcu Mehmet, Gungorduk Kemal, Aşıcıoğlu Osman, Çetinkaya Nilüfer, Güngör Tayfun, Pakay Gonca, Cüylan Zeliha Fırat, Toptaş Tayfun, Özyurt Ramazan, Ağaçayak Elif, Ozdemir Aykut, Erol Onur, Turan Anıl, Gülseren Varol, İcen Mehmet Sait, Şenol Taylan, Güraslan Hakan, Yücesoy Burcu, Sahbaz Ahmet, Gungorduk Ozgu, Besimoğlu Berhan, Pakay Kaan, Temizkan Osman, Sancı Muzaffer, Şimşek Tayup, Meydanlı Mehmet Mutlu, Harma Mehmet, Yaşar Levent, Boran Birtan, Uysal Aysel Derbent, Karateke Ateş
Department of Gynecology and Gynecologic Oncology, Izmir Tepecik Education and Research Hospital, Izmir, Turkey.
Department of Gynecology and Gynecologic Oncology, Mugla Sıtkı Kocman University Education and Research Hospital, Mentese, 48000, Mugla, Turkey.
J Ovarian Res. 2016 Oct 18;9(1):66. doi: 10.1186/s13048-016-0276-1.
The optimal surgical management and staging of borderline ovarian tumors (BOTs) are controversial. Institutions have different surgical approaches for the treatment of BOTs. Here, we performed a retrospective review of clinical characteristics, surgical management and surgical outcomes, and sought to identify variables affecting disease-free survival (DFS) and overall survival (OS) in patients with BOTs.
A retrospective review of ten gynecological oncology department databases in Turkey was conducted to identify patients diagnosed with BOTs. The effects of type of surgery, age, stage, surgical staging, complete versus incomplete staging, and adjuvant chemotherapy were examined on DFS and OS.
In total, 733 patients with BOTs were included in the analysis. Most of the staged cases were in stage IA (70.4 %). In total, 345 patients underwent conservative surgeries. Recurrence rates were similar between the conservative and radical surgery groups (10.5 % vs. 8.7 %). Furthermore we did not find any difference between DFS (HR = 0.96; 95 % confidence interval, CI = 0.7-1.2; p = 0.576) or OS (HR = 0.9; 95 % CI = 0.8-1.1; p = 0.328) between patients who underwent conservative versus radical surgeries. There was also no difference in DFS (HR = 0.74; 95 % CI = 0.8-1.1; p = 0.080) or OS (HR = 0.8; 95 % CI = 0.7-1.0; p = 0.091) between complete, incomplete, and unstaged patients. Furthermore, receiving adjuvant chemotherapy (CT) for tumor stage ≥ IC was not an independent prognostic factor for DFS or OS.
Patients undergoing conservative surgery did not show higher recurrence rates; furthermore, survival time was not shortened. Detailed surgical staging, including lymph node sampling or dissection, appendectomy, and hysterectomy, were not beneficial in the surgical management oF BOTs.
交界性卵巢肿瘤(BOTs)的最佳手术治疗及分期存在争议。各机构对BOTs的治疗采用不同的手术方法。在此,我们对临床特征、手术治疗及手术结果进行了回顾性分析,并试图确定影响BOTs患者无病生存期(DFS)和总生存期(OS)的变量。
对土耳其十个妇科肿瘤科室数据库进行回顾性分析,以确定诊断为BOTs的患者。研究了手术类型、年龄、分期、手术分期、完整分期与不完整分期以及辅助化疗对DFS和OS的影响。
共有733例BOTs患者纳入分析。大多数分期病例为IA期(70.4%)。共有345例患者接受了保守手术。保守手术组和根治手术组的复发率相似(10.5%对8.7%)。此外,我们发现接受保守手术与根治手术的患者在DFS(风险比[HR]=0.96;95%置信区间[CI]=0.7 - 1.2;p = 0.576)或OS(HR = 0.9;95% CI = 0.8 - 1.1;p = 0.328)方面没有差异。完整分期、不完整分期和未分期患者在DFS(HR = 0.74;95% CI = 0.8 - 1.1;p = 0.080)或OS(HR = 0.8;95% CI = 0.7 - 1.0;p = 0.091)方面也没有差异。此外,肿瘤分期≥IC期接受辅助化疗(CT)并非DFS或OS的独立预后因素。
接受保守手术的患者并未表现出更高的复发率;此外,生存时间也未缩短。详细的手术分期,包括淋巴结取样或清扫、阑尾切除术和子宫切除术,在BOTs的手术治疗中并无益处。